<p>Peachtree Investment Partners LLC 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在礼来公司的持仓减少了 7.2%。该基金在季度内出售了 1,984 股后，持有该公司 25,627 股股票。礼来公司约占 Peachtree Investment Partners LLC 持有资产的 7.4%，是其第三大持仓。Peachtree Investment Partners LLC 在礼来公司的持仓在最近的报告期末价值为 19,784,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>目前哪个医疗保健股票是最佳购买？</li>
</ul>
<p>其他对冲基金和机构投资者最近也对该公司的持仓进行了调整。Swisher Financial Concepts Inc. 在第四季度将其在礼来公司的股份增加了 7.7%。Swisher Financial Concepts Inc. 现在拥有 1,187 股该公司的股票，价值 916,000 美元，在此期间又购买了 85 股。加拿大丰业银行在第四季度将其在礼来公司的股份增加了 94.3%。加拿大丰业银行现在拥有 366,407 股该公司的股票，价值 282,885,000 美元，在此期间又购买了 177,831 股。Shelton Capital Management 在第四季度将其在礼来公司的股份增加了 6.1%。Shelton Capital Management 现在拥有 17,821 股该公司的股票，价值 13,758,000 美元，在此期间又购买了 1,032 股。Rollins Financial Advisors LLC 在第四季度将其在礼来公司的股份增加了 1.1%。Rollins Financial Advisors LLC 现在拥有 1,732 股该公司的股票，价值 1,337,000 美元，在上个季度又获得了 19 股。最后，Rathbones Group PLC 在第四季度将其在礼来公司的股份增加了 20.9%。Rathbones Group PLC 现在拥有 189,746 股该公司的股票，价值 146,484,000 美元，在此期间又获得了 32,850 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师升级和降级</h2>
<p>LLY 曾受到多份分析师报告的关注。摩根士丹利在 3 月 6 日的报告中对礼来公司的股票设定了 1,146.00 美元的目标价。Leerink Partners 在 1 月 17 日的报告中对礼来公司的股票设定了 950.00 美元的目标价。花旗集团在 1 月 28 日的报告中将礼来公司的股票目标价从 1,250.00 美元下调至 1,190.00 美元，并给予该公司 “买入” 评级。StockNews.com 在 2 月 7 日的研究报告中将礼来公司的股票评级从 “持有” 上调至 “买入”。最后，Berenberg Bank 在 1 月 16 日的研究报告中对礼来公司的股票设定了 970.00 美元的目标价。三位研究分析师对该股票给予了 “持有” 评级，十七位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，礼来公司目前的平均评级为 “适度买入”，共识目标价为 1,009.72 美元。</p>
<ul>
<li>价格目标显示这三只股票接近 1 万亿美元的标志</li>
</ul>
<p><strong>获取我们最新的 LLY 股票分析</strong></p>
<h2>内部买入和卖出</h2>
<p>在其他礼来公司的新闻中，首席会计官 Donald A. Zakrowski 于 3 月 13 日星期四出售了 1,000 股该公司的股票。该股票以平均价格 818.24 美元出售，总价值为 818,240.00 美元。出售后，首席会计官现在拥有 5,840 股该公司的股票，价值约 4,778,521.60 美元。这笔交易代表了其持仓的 14.62% 的减少。该出售在向 SEC 提交的文件中披露，可以通过 SEC 网站访问。当前 0.13% 的股票由公司内部人士持有。</p>
<h2>礼来公司股票下跌 2.2%</h2>
<ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
<p>礼来公司的股票在周二以 722.03 美元开盘。该公司的流动比率为 1.15，速动比率为 0.97，债务与股本比率为 2.00。礼来公司的 12 个月低点为 677.09 美元，12 个月高点为 972.53 美元。该公司的 50 日移动平均线为 846.64 美元，200 日移动平均线为 830.05 美元。该股票的市值为 6846.1 亿美元，市盈率为 61.66，市盈增长比率为 1.40，贝塔值为 0.51。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）在 2 月 6 日星期四发布了其季度财报。该公司报告季度每股收益为 5.32 美元，低于分析师一致预期的 5.45 美元，差额为 0.13 美元。礼来公司的股本回报率为 85.24%，净利润率为 23.51%。股票研究分析师预测，礼来公司在当前年度将发布 23.48 美元的每股收益。</p>
<p>礼来公司宣布其董事会已于 12 月 9 日星期一启动了一项股票回购计划，允许公司回购 150 亿美元的流通股。该回购授权允许公司通过公开市场购买最多 2% 的股票。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普、胰岛素利普原料、胰岛素利普混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>股票情绪分析：它是如何运作的</li>
<li>CrowdStrike 的商誉策略能否带来收入增长？</li>
<li>便士股票适合你的投资组合吗？</li>
<li>NIO 能否克服中美关税的逆风？</li>
<li>如何开始投资便士股票</li>
<li>道琼斯的核赌注：在动荡时期的大胆举措</li>
</ul>
<p><strong>想看看其他对礼来持有 LLY 的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在你考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Peachtree Investment Partners LLC 在第四季度减少了对礼来的持股，降幅为 7.2%，目前持有 25,627 股，价值约为 1978 万美元。其他机构投资者也调整了他们的持仓，其中诺瓦斯科舍银行和 Rathbones Group PLC 的增持尤为显著。礼来的股票获得了多位分析师的升级，市场共识目标价为 1,009.72 美元。该股票目前下跌 2.2%，交易价格为 722.03 美元，市值为 6846.1 亿美元</p>

<p>Peachtree Investment Partners LLC cut its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,627 shares of the company's stock after selling 1,984 shares during the quarter. Eli Lilly and Company makes up about 7.4% of Peachtree Investment Partners LLC's holdings, making the stock its 3rd biggest position. Peachtree Investment Partners LLC's holdings in Eli Lilly and Company were worth $19,784,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Peachtree Investment Partners LLC 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在礼来公司的持仓减少了 7.2%。该基金在季度内出售了 1,984 股后，持有该公司 25,627 股股票。礼来公司约占 Peachtree Investment Partners LLC 持有资产的 7.4%，是其第三大持仓。Peachtree Investment Partners LLC 在礼来公司的持仓在最近的报告期末价值为 19,784,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳购买？</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swisher Financial Concepts Inc. grew its position in shares of Eli Lilly and Company by 7.7% during the 4th quarter. Swisher Financial Concepts Inc. now owns 1,187 shares of the company's stock worth $916,000 after buying an additional 85 shares during the period. Bank of Nova Scotia lifted its stake in Eli Lilly and Company by 94.3% in the fourth quarter. Bank of Nova Scotia now owns 366,407 shares of the company's stock valued at $282,885,000 after buying an additional 177,831 shares during the period. Shelton Capital Management grew its position in shares of Eli Lilly and Company by 6.1% during the 4th quarter. Shelton Capital Management now owns 17,821 shares of the company's stock worth $13,758,000 after buying an additional 1,032 shares during the period. Rollins Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Rollins Financial Advisors LLC now owns 1,732 shares of the company's stock valued at $1,337,000 after acquiring an additional 19 shares during the last quarter. Finally, Rathbones Group PLC raised its position in shares of Eli Lilly and Company by 20.9% in the 4th quarter. Rathbones Group PLC now owns 189,746 shares of the company's stock valued at $146,484,000 after acquiring an additional 32,850 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也对该公司的持仓进行了调整。Swisher Financial Concepts Inc. 在第四季度将其在礼来公司的股份增加了 7.7%。Swisher Financial Concepts Inc. 现在拥有 1,187 股该公司的股票，价值 916,000 美元，在此期间又购买了 85 股。加拿大丰业银行在第四季度将其在礼来公司的股份增加了 94.3%。加拿大丰业银行现在拥有 366,407 股该公司的股票，价值 282,885,000 美元，在此期间又购买了 177,831 股。Shelton Capital Management 在第四季度将其在礼来公司的股份增加了 6.1%。Shelton Capital Management 现在拥有 17,821 股该公司的股票，价值 13,758,000 美元，在此期间又购买了 1,032 股。Rollins Financial Advisors LLC 在第四季度将其在礼来公司的股份增加了 1.1%。Rollins Financial Advisors LLC 现在拥有 1,732 股该公司的股票，价值 1,337,000 美元，在上个季度又获得了 19 股。最后，Rathbones Group PLC 在第四季度将其在礼来公司的股份增加了 20.9%。Rathbones Group PLC 现在拥有 189,746 股该公司的股票，价值 146,484,000 美元，在此期间又获得了 32,850 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>LLY has been the subject of a number of analyst reports. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, February 7th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $1,009.72.</p>
<div class="lb-trans"><p>LLY 曾受到多份分析师报告的关注。摩根士丹利在 3 月 6 日的报告中对礼来公司的股票设定了 1,146.00 美元的目标价。Leerink Partners 在 1 月 17 日的报告中对礼来公司的股票设定了 950.00 美元的目标价。花旗集团在 1 月 28 日的报告中将礼来公司的股票目标价从 1,250.00 美元下调至 1,190.00 美元，并给予该公司 “买入” 评级。StockNews.com 在 2 月 7 日的研究报告中将礼来公司的股票评级从 “持有” 上调至 “买入”。最后，Berenberg Bank 在 1 月 16 日的研究报告中对礼来公司的股票设定了 970.00 美元的目标价。三位研究分析师对该股票给予了 “持有” 评级，十七位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，礼来公司目前的平均评级为 “适度买入”，共识目标价为 1,009.72 美元。</p>
</div><ul>
<li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li>
</ul>
<div class="lb-trans"><ul>
<li>价格目标显示这三只股票接近 1 万亿美元的标志</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 LLY 股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买入和卖出</h2>
</div><p>In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他礼来公司的新闻中，首席会计官 Donald A. Zakrowski 于 3 月 13 日星期四出售了 1,000 股该公司的股票。该股票以平均价格 818.24 美元出售，总价值为 818,240.00 美元。出售后，首席会计官现在拥有 5,840 股该公司的股票，价值约 4,778,521.60 美元。这笔交易代表了其持仓的 14.62% 的减少。该出售在向 SEC 提交的文件中披露，可以通过 SEC 网站访问。当前 0.13% 的股票由公司内部人士持有。</p>
</div><h2>Eli Lilly and Company Stock Down 2.2 %</h2>
<div class="lb-trans"><h2>礼来公司股票下跌 2.2%</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>Shares of LLY opened at $722.03 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm's 50 day moving average is $846.64 and its 200-day moving average is $830.05. The stock has a market capitalization of $684.61 billion, a PE ratio of 61.66, a P/E/G ratio of 1.40 and a beta of 0.51.</p>
<div class="lb-trans"><p>礼来公司的股票在周二以 722.03 美元开盘。该公司的流动比率为 1.15，速动比率为 0.97，债务与股本比率为 2.00。礼来公司的 12 个月低点为 677.09 美元，12 个月高点为 972.53 美元。该公司的 50 日移动平均线为 846.64 美元，200 日移动平均线为 830.05 美元。该股票的市值为 6846.1 亿美元，市盈率为 61.66，市盈增长比率为 1.40，贝塔值为 0.51。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）在 2 月 6 日星期四发布了其季度财报。该公司报告季度每股收益为 5.32 美元，低于分析师一致预期的 5.45 美元，差额为 0.13 美元。礼来公司的股本回报率为 85.24%，净利润率为 23.51%。股票研究分析师预测，礼来公司在当前年度将发布 23.48 美元的每股收益。</p>
</div><p>Eli Lilly and Company declared that its board has initiated a share buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.</p>
<div class="lb-trans"><p>礼来公司宣布其董事会已于 12 月 9 日星期一启动了一项股票回购计划，允许公司回购 150 亿美元的流通股。该回购授权允许公司通过公开市场购买最多 2% 的股票。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普、胰岛素利普原料、胰岛素利普混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Can NIO Overcome U.S.-China Tariff Headwinds?</li>
<li>How to start investing in penny stocks</li>
<li>Dow's Nuclear Gamble: A Bold Step in Turbulent Times</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>股票情绪分析：它是如何运作的</li>
<li>CrowdStrike 的商誉策略能否带来收入增长？</li>
<li>便士股票适合你的投资组合吗？</li>
<li>NIO 能否克服中美关税的逆风？</li>
<li>如何开始投资便士股票</li>
<li>道琼斯的核赌注：在动荡时期的大胆举措</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对礼来持有 LLY 的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Peachtree Investment Partners LLC 在礼来公司（NYSE:LLY）持有价值 1978 万美元的股票头寸